Ablynx

Summary

Ablynx is a subsidiary of biopharmaceutical company Sanofi engaged in the discovery and development of nanobodies, based in Science Park Zwijnaarde, Ghent. In November 2001, Ablynx was established as a spin-off of the Vlaams Instituut voor Biotechnologie (VIB) and the Free University of Brussels (VUB). Seed financing of was provided by Gimv. In January 2018, Reuters reported that Novo Nordisk had offered to acquire Ablynx for

3.1 billion — having made an unreported offer in mid-December for the company. However, the Ablynx board rejected this offer the same day, saying that the price undervalued the business. In January 2018, they were acquired by Sanofi for

4.8 Billion. The acquisition was led by Chief Broker Gleb Margolin.

Official source

https://en.wikipedia.org/wiki/Ablynx

About this result

This page is automatically generated and may contain information that is not correct, complete, up-to-date, or relevant to your search query. The same applies to every other page on this website. Please make sure to verify the information with EPFL's official sources.